CAC Software vs Zio AT ECG Monitoring System

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

CAC Software

by 4DMedical (Imbio CAC Software)

Zio AT ECG Monitoring System

by iRhythm Technologies, Inc.

AI Verdict

These tools are adjacent in their application, both leveraging AI for cardiac care but addressing distinct clinical needs. Tool A focuses on quantifying coronary artery calcification from CT scans to assess cardiovascular disease risk, while Tool B provides continuous ECG monitoring via a wearable device for long-term arrhythmia detection and reporting. Therefore, the choice between them depends on whether the clinical focus is on structural risk assessment or electrical activity monitoring.

Choose CAC Software if…

Choose Imbio's CAC Software if you need to assess a patient's risk for coronary artery disease by quantifying calcification from an existing non-contrast chest CT scan. This tool is ideal for leveraging incidental findings from routine imaging to provide a non-invasive, AI-powered cardiac risk stratification without requiring additional patient procedures or radiation exposure.

View CAC Software →

Choose Zio AT ECG Monitoring System if…

Choose iRhythm's Zio AT ECG Monitoring System if you require continuous, long-term (up to 14 days) arrhythmia detection for patients experiencing intermittent cardiac symptoms. This wearable system is best suited for identifying elusive symptomatic and asymptomatic cardiac events through AI-powered ECG analysis and real-time data transmission, providing comprehensive reports for diagnosis and management.

View Zio AT ECG Monitoring System →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	CAC Software	Zio AT ECG Monitoring System
Pricing	Unknown	Contact for pricing
Deployment	Cloud-based (SaaS), integrates with PACS	Cloud-based (data analytics and clinician portal)
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

CAC Software

Tool A seamlessly integrates into existing DICOM viewing workflows, minimizing disruption for radiologists and cardiologists. Its automated, non-invasive analysis and clear visualizations enhance efficiency within established clinical practices.

Clinical Value

Tie

Both tools offer significant and validated clinical value in distinct areas of cardiology, addressing critical needs for CAD risk stratification and arrhythmia detection respectively. Both are FDA-cleared, confirming their efficacy and safety for clinical use.

Pricing & Value

Tie

Neither tool provides publicly disclosed pricing information, making a direct comparison of their cost-effectiveness or overall value impossible. Both require direct contact for pricing details, which is common in enterprise healthcare solutions.

Enterprise Readiness

CAC Software

Tool A offers greater deployment flexibility with options for cloud, on-premise, or partner platforms, which can be crucial for diverse enterprise IT environments. Both tools meet essential compliance standards like HIPAA and FDA clearance.

Innovation

Zio AT ECG Monitoring System

Tool B demonstrates higher innovation by combining a novel wearable device with AI for continuous, long-term remote cardiac monitoring and real-time data transmission. This integrated hardware and software solution extends care beyond traditional clinic settings.

Support & Docs

Zio AT ECG Monitoring System

Tool B offers explicit 24/7 phone support for providers and comprehensive patient-facing resources, including app-based support and instructional videos. While Tool A offers 24/7 email/web support, Tool B's transparent and multi-channel approach for both clinicians and patients gives it an edge.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	CAC Software	Zio AT ECG Monitoring System
Name	CAC Software	Zio AT ECG Monitoring System
Company	Imbio	iRhythm Technologies, Inc.
Primary Function	Automated image post-processing for determining and quantifying coronary artery calcification from non-contrast chest CT.	Wearable mobile cardiac telemetry (MCT) service for continuous, AI-powered ECG monitoring for long-term arrhythmia detection.
Categories	Cardiology AI	Cardiology AI, Wearables & Remote Monitoring (RPM)
Specialties	Cardiology, Radiology	Cardiology
Key Outputs/Detections	Agatston score, arterial age, calcified lesion mass and volume, 3D visualizations, annotated images.	Arrhythmia detection, comprehensive end-of-wear reports, detection of symptomatic and asymptomatic cardiac events.
Core Technology/Method	Deep-learning based analysis, automated image post-processing from non-contrast chest CT scans.	Wearable Zio AT patch for continuous ECG recording, wireless gateway for real-time data transmission, FDA-cleared deep-learned AI algorithm (ZEUS System).

Videos

Demos, reviews, and walkthroughs featuring CAC Software and Zio AT ECG Monitoring System.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into a physician's existing clinical workflow and EHR for seamless data access and patient management?

Imbio's CAC Software integrates directly into existing DICOM viewing workflows, allowing for automated image post-processing within familiar radiology and cardiology environments. The Zio AT ECG Monitoring System utilizes a dedicated ZioSuiteu00ae clinician portal and mobile app for patient management and report interpretation, with real-time data transmission from the wearable patch.

What is the reported accuracy or sensitivity of each tool's AI algorithms in detecting their respective cardiac conditions (coronary artery calcification vs. arrhythmias)?

Imbio's CAC Software employs deep-learning based analysis to quantify coronary artery calcification, providing specific Agatston scores, arterial age, and calcified lesion mass/volume. The Zio AT ECG Monitoring System uses an FDA-cleared deep-learned AI algorithm (ZEUS System) for continuous, uninterrupted ECG monitoring and comprehensive arrhythmia detection over up to 14 days.

Beyond the stated specialties, what specific clinical scenarios or patient populations are each tool best suited for, and how do they complement existing diagnostic pathways?

Imbio's CAC Software is ideal for risk assessment of coronary artery disease in patients who have undergone non-contrast chest CT scans, complementing existing cardiovascular risk stratification. The Zio AT ECG Monitoring System is designed for long-term detection of symptomatic and asymptomatic cardiac arrhythmias, providing extended monitoring for patients where intermittent ECGs may miss events.

What is the expected learning curve for physicians and their staff to effectively utilize each tool, from patient setup or image input to report interpretation, and what training is provided?

Imbio's CAC Software integrates into familiar DICOM viewing workflows, potentially reducing the learning curve for radiologists and cardiologists in interpreting the automated analysis and 3D visualizations. The Zio AT system involves patient application of a wearable patch, use of a patient mobile app for symptom logging, and navigation of the ZioSuiteu00ae clinician portal for data review and management.

How quickly can a practice expect to see clinical or operational value after implementing each tool, considering the typical patient pathway and data processing times?

Imbio's CAC Software offers automated analysis from existing CT scans, potentially providing rapid insights for CAD risk assessment and streamlining image interpretation workflows. The Zio AT system requires up to 14 days of continuous patient monitoring before generating comprehensive end-of-wear reports, with value realized through long-term arrhythmia detection and diagnosis.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring CAC Software or Zio AT ECG Monitoring System

Backers

Who funded each tool's parent company.